# **Data Changes for the CCDD APR Release Candidate 2021**

## **Based on the QA Release** 20210401

|  |  |
| --- | --- |
| Data entered by | J. Hutsul |
| Data checked by | B. Prime |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8001709 | calcium carbonate and etidronate |

## **NTP File**

### **Deprecation**

The following NTP concept(s) need to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  |  |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
| 9014119 | nonacog alfa 1000 unit per vial powder for solution for injection with diluent solution syringe | e02b399a94f42c26f564da70cbbd0b88 |
| 9014120 | nonacog alfa 2000 unit per vial powder for solution for injection with diluent solution syringe | 99a45cf99ffb4f9f6c8919744a6a664a |
| 9014121 | nonacog alfa 3000 unit per vial powder for solution for injection with diluent solution syringe | 770c7dcfe1cc69c5638cd92c8958311e |
| 9014122 | nonacog alfa 500 unit per vial powder for solution for injection with diluent solution syringe | 3b9e9552a3033bd338ed62020254be74 |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9012601 | alirocumab 150 mg per 1 mL solution for injection syringe |
| 9012603 | alirocumab 75 mg per 1 mL solution for injection syringe |
| 9004601 | aliskiren (aliskiren fumarate) 150 mg and hydrochlorothiazide 12.5 mg oral tablet |
| 9004603 | aliskiren (aliskiren fumarate) 300 mg and hydrochlorothiazide 12.5 mg oral tablet |
| 9013036 | calcium (calcium carbonate) 500 mg oral tablet with etidronate disodium 400 mg oral tablet |

## **MP File**

### **Deprecation (very rare)**

**No new deprecated concepts**

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For both DINs, they have had additional UoP added. Both products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
| 02182971 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 1000 mg par 40 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02182777 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 500 mg par 20 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |

The following MP concepts are generating as active but need to be set to **deprecated**. For both products, they have been assigned a new DIN (02474891, 02474735). This will have to be done manually each month.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
| 77700322 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700323 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
| 94649 | 2459299 | AMGEVITA (adalimumab 40 mg per 0.8 mL solution for injection syringe) AMGEN CANADA INC | SINGLE-USE PREFILLED SYRINGE (40MG/0.8ML) | SINGLE-USE PREFILLED SYRINGE (40MG/0.8ML) |
| 94650 | 2459302 | AMGEVITA (adalimumab 40 mg per 0.8 mL solution for injection syringe) AMGEN CANADA INC | SINGLE-USE PREFILLED AUTOINJECTOR (40MG/0.8ML) | SINGLE-USE PREFILLED AUTOINJECTOR (40MG/0.8ML) |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 74925 | 2263866 | ACT ETIDROCAL (calcium (calcium carbonate) 500 mg oral tablet with etidronate disodium 400 mg oral tablet) TEVA CANADA LIMITED | Cancelled post-market 2021.03.05 |
| 74810 | 2262746 | ACT PAROXETINE (paroxetine (paroxetine hydrochloride) 10 mg oral tablet) ACTAVIS PHARMA COMPANY | Cancelled post-market Expiry 2021.03.31 |
| 74811 | 2262754 | ACT PAROXETINE (paroxetine (paroxetine hydrochloride) 20 mg oral tablet) ACTAVIS PHARMA COMPANY | Cancelled post-market Expiry 2021.03.31 |
| 73096 | 2248728 | APO-ALENDRONATE (alendronic acid (alendronate sodium) 10 mg oral tablet) APOTEX INC | Dormant 2021.03.16 |
| 85641 | 2371235 | APO-LOSARTAN/HCTZ (hydrochlorothiazide 12.5 mg and losartan potassium 50 mg oral tablet) APOTEX INC | Dormant 2019.12.21 |
| 85643 | 2371251 | APO-LOSARTAN/HCTZ (hydrochlorothiazide 25 mg and losartan potassium 100 mg oral tablet) APOTEX INC | Dormant 2019.12.22 |
| 79043 | 2305062 | APO-METFORMIN ER (metformin hydrochloride 500 mg prolonged-release oral tablet) APOTEX INC | Dormant 2020.11.28 |
| 88766 | 2402823 | APO-OLOPATADINE (olopatadine (olopatadine hydrochloride) 0.2 % ophthalmic drops) APOTEX INC | Dormant 2021.01.18 |
| 76651 | 2280833 | APO-RANITIDINE (ranitidine (ranitidine hydrochloride) 75 mg per 5 mL oral solution) APOTEX INC | Dormant 2020.09.14 |
| 7426 | 733059 | APO-RANITIDINE TABLET 150MG (ranitidine (ranitidine hydrochloride) 150 mg oral tablet) APOTEX INC | Dormant 2020.09.13 |
| 7427 | 733067 | APO-RANITIDINE TABLET 300MG (ranitidine (ranitidine hydrochloride) 300 mg oral tablet) APOTEX INC | Dormant 2020.09.13 |
| 90033 | 2415739 | APO-TRAVOPROST Z (travoprost 0.004 % ophthalmic drops) APOTEX INC | Dormant 2020.12.05 |
| 13305 | 1984845 | BONEFOS (clodronate disodium (clodronate disodium tetrahydrate) 400 mg oral capsule) BAYER INC | Cancelled post-market  Expiry 2021.03.31 |
| 73510 | 2250306 | CEFTRIAXONE SODIUM FOR INJECTION BP (ceftriaxone (ceftriaxone sodium) 2 g per vial powder for solution for injection) PFIZER CANADA ULC | Cancelled post-market 2021.03.24 |
| 79404 | 2308398 | DOM-ALENDRONATE-FC (alendronic acid (alendronate sodium) 70 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 81218 | 2326841 | DOM-AMLODIPINE (amlodipine (amlodipine besylate) 10 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 81217 | 2326833 | DOM-AMLODIPINE (amlodipine (amlodipine besylate) 5 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 76408 | 2278499 | DOM-AZITHROMYCIN (azithromycin (azithromycin monohydrate hemiethanolate) 250 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 75855 | 2273055 | DOM-CITALOPRAM (citalopram (citalopram hydrobromide) 10 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 73317 | 2248942 | DOM-CITALOPRAM (citalopram (citalopram hydrobromide) 20 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 73318 | 2248943 | DOM-CITALOPRAM (citalopram (citalopram hydrobromide) 40 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 83618 | 2351005 | DOM-CLARITHROMYCIN (clarithromycin 500 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 86430 | 2378507 | DOM-CLOPIDOGREL (clopidogrel (clopidogrel bisulfate) 75 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 86225 | 2376709 | DOM-FINASTERIDE (finasteride 5 mg oral tablet) DOMINION PHARMACAL | Dormant 2021.03.19 |
| 86257 | 2376997 | DULCOCOMFORT STOOL SOFTENER (docusate sodium 100 mg oral capsule) SANOFI CONSUMER HEALTH INC | Dormant 2021.03.17 |
| 73852 | 2253550 | MEDROXY-2.5 (medroxyprogesterone acetate 2.5 mg oral tablet) PRO DOC LIMITEE | Cancelled post-market  Expiry 2021.03.31 |
| 891 | 2162806 | MINITRAN (nitroglycerin 0.2 mg per hour transdermal patch) VALEANT CANADA LP/VALEANT CANADA S.E.C. | Dormant 2021.03.19 |
| 19028 | 2163535 | MINITRAN (nitroglycerin 0.6 mg per hour transdermal patch) VALEANT CANADA LP/VALEANT CANADA S.E.C. | Dormant 2021.03.19 |
| 88272 | 2397803 | MINT-ROSUVASTATIN (rosuvastatin (rosuvastatin calcium) 10 mg oral tablet) MINT PHARMACEUTICALS INC | Cancelled post-market  Expiry 2021.03.31 |
| 88273 | 2397811 | MINT-ROSUVASTATIN (rosuvastatin (rosuvastatin calcium) 20 mg oral tablet) MINT PHARMACEUTICALS INC | Cancelled post-market  Expiry 2021.03.31 |
| 88274 | 2397838 | MINT-ROSUVASTATIN (rosuvastatin (rosuvastatin calcium) 40 mg oral tablet) MINT PHARMACEUTICALS INC | Cancelled post-market  Expiry 2021.03.31 |
| 88271 | 2397781 | MINT-ROSUVASTATIN (rosuvastatin (rosuvastatin calcium) 5 mg oral tablet) MINT PHARMACEUTICALS INC | Cancelled post-market  Expiry 2021.03.31 |
| 94030 | 2453762 | PRALUENT (alirocumab 150 mg per 1 mL solution for injection syringe) SANOFI-AVENTIS CANADA INC | Cancelled post-market 2021.03.04 |
| 94029 | 2453754 | PRALUENT (alirocumab 75 mg per 1 mL solution for injection syringe) SANOFI-AVENTIS CANADA INC | Cancelled post-market 2021.03.04 |
| 78477 | 2299372 | RAMIPRIL (ramipril 1.25 mg oral capsule) LABORATOIRE RIVA INC. | Dormant 2021.03.10 |
| 74194 | 2256711 | RANITIDINE INJECTION USP (ranitidine (ranitidine hydrochloride) 50 mg per 2 mL solution for injection vial) SANDOZ CANADA INCORPORATED | Cancelled post-market 2021.03.01 |
| 81838 | 2332728 | RASILEZ HCT (aliskiren (aliskiren fumarate) 150 mg and hydrochlorothiazide 12.5 mg oral tablet) NODEN PHARMA DAC | Cancelled post-market Expiry 2021.03.31 |
| 81840 | 2332744 | RASILEZ HCT (aliskiren (aliskiren fumarate) 300 mg and hydrochlorothiazide 12.5 mg oral tablet) NODEN PHARMA DAC | Cancelled post-market Expiry 2021.03.31 |
| 81585 | 2330091 | RIVA-RABEPRAZOLE EC (rabeprazole sodium 20 mg gastro-resistant tablet) LABORATOIRE RIVA INC. | Cancelled post-market Expiry 2021.03.31 |
| 69767 | 2245667 | SANDOZ CYPROHEPTADINE TABLET (cyproheptadine hydrochloride 4 mg oral tablet) SANDOZ CANADA INCORPORATED | Cancelled post-market Expiry 2021.03.31 |
| 67115 | 2243229 | SANDOZ RANITIDINE (ranitidine (ranitidine hydrochloride) 150 mg oral tablet) SANDOZ CANADA INCORPORATED | Cancelled post-market 2021.03.01 |
| 67116 | 2243230 | SANDOZ RANITIDINE (ranitidine (ranitidine hydrochloride) 300 mg oral tablet) SANDOZ CANADA INCORPORATED | Cancelled post-market 2021.03.01 |
| 16949 | 2108151 | TEVA-MINOCYCLINE (minocycline (minocycline hydrochloride) 100 mg oral capsule) TEVA CANADA LIMITED | Cancelled post-market 2021.03.01 |
| 85208 | 2367289 | VIRAMUNE XR (nevirapine 400 mg prolonged-release oral tablet) BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Cancelled post-market Expiry 2021.03.31 |

## **Blacklist (on GitHub)**

The following changes have been made to the Blacklist for the OCT Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 76db789eab661b8ef294734bb4f4fde2 | adalimumab 20 mg per 0.4 mL solution for injection syringe | 99460 | 02505258 | HYRIMOZ (adalimumab 20 mg per 0.4 mL solution for injection syringe) SANDOZ CANADA INCORPORATED | REMOVE |
| 9014442 | adalimumab 40 mg per 0.8 mL solution for injection pen | 98214 | 02492156 | HYRIMOZ (adalimumab 40 mg per 0.8 mL solution for injection pen) SANDOZ CANADA INCORPORATED | REMOVE |
| 9014443 | adalimumab 40 mg per 0.8 mL solution for injection syringe | 98215 | 02492164 | HYRIMOZ (adalimumab 40 mg per 0.8 mL solution for injection syringe) SANDOZ CANADA INCORPORATED | REMOVE |
| 9013005 | melphalan (melphalan hydrochloride) 50 mg per vial powder for solution for injection with diluent solution | 97057 | 02480026 | TARO-MELPHALAN (melphalan (melphalan hydrochloride) 50 mg per vial powder for solution for injection with diluent solution) TARO PHARMACEUTICALS INC | REMOVE |
| 66623d7dee9f5c8ac1d0f9bb58e40efd | ozanimod (ozanimod hydrochloride) 0.23 mg oral capsule with ozanimod (ozanimod hydrochloride) 0.46 mg oral capsule | 99536 | 02506009 | ZEPOSIA (ozanimod (ozanimod hydrochloride) 0.23 mg oral capsule with ozanimod (ozanimod hydrochloride) 0.46 mg oral capsule) CELGENE INC | REMOVE |